首页> 美国卫生研究院文献>PLoS Clinical Trials >Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation

【2h】

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation

机译：达比加群与华法林基因型引导治疗房颤患者卒中预防的成本效果比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost-effectiveness of dabigatran compared with warfain. We examined the cost-effectiveness of dabigatran versus warfarin therapy with genotype-guided management in patients with atrial fibrillation (AF).

机译：当抗凝控制不佳时，与华法林相比，背景达比加群与卒中发生率降低相关。基因型指导的华法林剂量和管理可能会缩短目标范围（TTR）中的患者时间，因此与华法林相比，会影响达比加群的成本效益。我们研究了达比加群与华法林联合基因型指导治疗在房颤（AF）患者中的成本效益。

著录项

期刊名称 PLoS Clinical Trials
作者
Joyce H. S. You; Kia K. N. Tsui; Raymond S. M. Wong; Gergory Cheng;
展开▼
作者单位

展开▼
年(卷),期 2009(7),6
年度 2009
页码 e39640
总页数 9
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation [J] . AlliO., DoshiS., KarS., Journal of the American College of Cardiology . 2013,第17期

机译：在有非瓣膜性心房纤颤风险的中风患者的随机PROTECT AF（左房附件经皮封闭与华法林预防心房纤颤的治疗）中的生活质量评估
2. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack [J] . KamelH., JohnstonS.C., EastonJ.D., Stroke: A Journal of Cerebral Circulation . 2012,第3期

机译：达比加群与华法林相比在房颤和既往中风或短暂性脑缺血发作患者中预防卒中的成本效益
3. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model [J] . Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Thrombosis Journal . 2013,第1期

机译：标准或药物遗传学指导管理下的达比加群与华法林预防房颤患者中风和全身血栓栓塞的发生：采用分析决策模型的成本/效用分析
4. Group-Based Trajectory Analysis for Long-Term Use of Warfarin Therapy in Atrial Fibrillation Patients [C] . Shijing Guo, Xiang Li, Xin Du, MEDINFO . 2017

机译：基于组的术语轨迹分析，用于高级患者的华法林治疗
5. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
6. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model [O] . Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, 2013

机译：标准或药物遗传学指导管理下的达比加群与华法林预防房颤患者中风和全身血栓栓塞的发生：采用分析决策模型的成本/效用分析
7. Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation [O] . You, Joyce H. S., Tsui, Kia K. N., Wong, Raymond S. M., 2012

机译：达比加群与华法林基因型指导治疗房颤患者卒中预防的成本效果比较

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅